In Silico Study of the Acquired Resistance Caused by the Secondary Mutations of KRAS G12C Protein Using Long Time Molecular Dynamics Simulation and Markov State Model Analysis

Kirsten rat sarcoma viral oncogene homolog (KRAS) is a small GTPase protein which plays an important role in the treatment of KRAS mutant cancers. The FDA-approved AMG510 and MRTX849 (phase III clinical trials) are two potent KRASG12C-selective inhibitors that target KRAS G12C. However, the drug res...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Gao, Liu, Qing, Qiu, Yue, Leung, Elaine Lai-Han, Yao, Xiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694466/
https://www.ncbi.nlm.nih.gov/pubmed/36430323
http://dx.doi.org/10.3390/ijms232213845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694466/
https://www.ncbi.nlm.nih.gov/pubmed/36430323
http://dx.doi.org/10.3390/ijms232213845

Ejemplares similares